This is in line with a meta-analysis by Valanchis4, stating that there is no significant difference in breast-cancer-specific survival between BRCA1/2 carriers who undergo contralateral RRM and breast conserving therapy. This evidence concerns the gene BRCA1 and breast carcinoma.